

# David Bowtell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1959428/david-bowtell-publications-by-year.pdf>

**Version:** 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182  
papers

28,901  
citations

76  
h-index

169  
g-index

194  
ext. papers

33,884  
ext. citations

12.1  
avg, IF

7.97  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 182 | TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102108                      | 2.2  |           |
| 181 | REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 374-381 | 4.9  | 4         |
| 180 | Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , <b>2021</b> , 42, 785-793  | 4.6  | 1         |
| 179 | Population-based targeted sequencing of 54 candidate genes identifies a susceptibility gene for high-grade serous ovarian cancer. <i>Journal of Medical Genetics</i> , <b>2021</b> , 58, 305-313                                | 5.8  | 12        |
| 178 | Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. <i>Journal of Pathology</i> , <b>2021</b> , 253, 41-54  | 9.4  | 15        |
| 177 | Prognostic gene expression signature for high-grade serous ovarian cancer. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1240-1250  | 10.3 | 37        |
| 176 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5411-5423                                   | 12.9 | 21        |
| 175 | Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 793-802              | 8.7  | 16        |
| 174 | Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 702-709  | 4.9  | 5         |
| 173 | The evolutionary history of 2,658 cancers. <i>Nature</i> , <b>2020</b> , 578, 122-128   | 50.4 | 307       |
| 172 | Pan-cancer analysis of whole genomes. <i>Nature</i> , <b>2020</b> , 578, 82-93  | 50.4 | 840       |
| 171 | Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. <i>Nature Genetics</i> , <b>2020</b> , 52, 331-341   | 36.3 | 168       |
| 170 | ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2225-2238   | 7.5  | 5         |
| 169 | Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 552-560  | 4.9  | 21        |
| 168 | Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5937-5946  | 12.9 | 21        |
| 167 | Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , <b>2019</b> , 19, 339-348  | 31.3 | 17        |
| 166 | Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3962-3973                         | 12.9 | 16        |

|     |  |      |     |
|-----|--|------|-----|
| 165 | Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , <b>2019</b> , 125, 1963-1972  | 6.4  | 22  |
| 164 | Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 2281-2293  | 6.6  | 15  |
| 163 | Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1940-1945  | 15.9 | 19  |
| 162 | Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-18  | 3.6  |     |
| 161 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 307-320   | 6.4  | 14  |
| 160 | Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer. <i>Cancer Informatics</i> , <b>2018</b> , 17, 1176935118755341  | 2.4  | 3   |
| 159 | Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis. <i>Cancer Research</i> , <b>2018</b> , 78, 1383-1391       | 10.1 | 19  |
| 158 | Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 680-688 | 4    | 1   |
| 157 | Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 569-580     | 12.9 | 46  |
| 156 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , <b>2018</b> , 4, 250-261                | 5.3  | 38  |
| 155 | Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 87   | 4.8  | 23  |
| 154 | Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky047   | 4.6  | 7   |
| 153 | 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 327-336     | 4.9  | 20  |
| 152 | Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 239-246                                   | 4.9  | 17  |
| 151 | Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4086-4094   | 12.9 | 83  |
| 150 | Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1274-1280                                     | 2.2  | 122 |
| 149 | Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 984-998                                    | 24.4 | 193 |
| 148 | A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. <i>Cancer Research</i> , <b>2017</b> , 77, 971-981   | 10.1 | 64  |

|     |  |      |     |
|-----|--|------|-----|
| 147 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, e173290  | 13.4 | 152 |
| 146 | Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. <i>Journal of Molecular Medicine</i> , <b>2017</b> , 95, 1167-1178  | 5.5  | 23  |
| 145 | and Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. <i>Cancer Research</i> , <b>2017</b> , 77, 4268-4278  | 10.1 | 32  |
| 144 | Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5912-5922   | 12.9 | 31  |
| 143 | Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1862-1874   | 12.9 | 78  |
| 142 | Long-term survival of patients with mismatch repair protein-deficient, high-stage ovarian clear cell carcinoma. <i>Histopathology</i> , <b>2017</b> , 70, 309-313  | 7.3  | 22  |
| 141 | Acquired chemotherapy resistance in ovarian cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, viii13-viii15  | 10.3 | 77  |
| 140 | Germline whole exome sequencing and large-scale replication identifies as a likely high grade serous ovarian cancer susceptibility gene. <i>Oncotarget</i> , <b>2017</b> , 8, 50930-50940  | 3.3  | 30  |
| 139 | Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1386-1395  | 21.7 | 251 |
| 138 | The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 5460-5471 | 5.6  | 20  |
| 137 | Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1813-24   | 12.9 | 21  |
| 136 | The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002204  | 11.6 | 81  |
| 135 | Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5553-5553   | 2.2  | 1   |
| 134 | Commentary on "Epithelial-to-Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer". <i>Cancer Research</i> , <b>2016</b> , 76, 7075-7077   | 10.1 | 1   |
| 133 | A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 1010-1014   | 44.5 | 46  |
| 132 | Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. <i>Cancer Research</i> , <b>2016</b> , 76, 5590-5591  | 11   | 4   |
| 131 | Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 458-64  | 4.9  | 13  |
| 130 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 164-71  | 36.3 | 177 |

|     |   |      |     |
|-----|---|------|-----|
| 129 | Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1495-503   | 6.1  | 13  |
| 128 | Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 1255-64   | 10.1 | 35  |
| 127 | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , <b>2015</b> , 15, 668-79   | 31.3 | 581 |
| 126 | Connecting patients, researchers and clinical genetics services: the experiences of participants in the Australian Ovarian Cancer Study (AOCS). <i>European Journal of Human Genetics</i> , <b>2015</b> , 23, 152-8   | 5.3  | 10  |
| 125 | Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2901-7  | 2.2  | 200 |
| 124 | Efficient molecular subtype classification of high-grade serous ovarian cancer. <i>Journal of Pathology</i> , <b>2015</b> , 236, 272-7  | 9.4  | 63  |
| 123 | Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. <i>Oncotarget</i> , <b>2015</b> , 6, 37663-77  | 3.3  | 98  |
| 122 | Development and validation of a gene expression tumour classifier for cancer of unknown primary. <i>Pathology</i> , <b>2015</b> , 47, 7-12  | 1.6  | 26  |
| 121 | Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , <b>2015</b> , 521, 489-94   | 50.4 | 890 |
| 120 | UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , <b>2015</b> , 75, 5228-34  | 10.1 | 196 |
| 119 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 652-7   | 12.9 | 107 |
| 118 | The ubiquitin ligase Siah is a novel regulator of Zeb1 in breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 862-73  | 3.3  | 37  |
| 117 | Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. <i>Cancer Research</i> , <b>2014</b> , 74, 1141-52   | 10.1 | 102 |
| 116 | Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Molecular Oncology</i> , <b>2014</b> , 8, 656-68   | 7.9  | 97  |
| 115 | Siah2 regulates tight junction integrity and cell polarity through control of ASPP2 stability. <i>Oncogene</i> , <b>2014</b> , 33, 2004-10  | 9.2  | 17  |
| 114 | Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. <i>Scientific Reports</i> , <b>2014</b> , 4, 4669   | 4.9  | 20  |
| 113 | Processed pseudogenes acquired somatically during cancer development. <i>Nature Communications</i> , <b>2014</b> , 5, 3644  | 17.4 | 68  |
| 112 | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 2297-307 | 8.7  | 49  |

|     |  |      |     |
|-----|--|------|-----|
| 111 | Fine tuning of the UPR by the ubiquitin ligases Siah1/2. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004348   | 6    | 27  |
| 110 | Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6618-30       | 12.9 | 66  |
| 109 | Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 4614-28   | 15.9 | 189 |
| 108 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 853-62  | 21.7 | 248 |
| 107 | Synthetic lethality between CCNE1 amplification and loss of BRCA1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 19489-94  | 11.5 | 142 |
| 106 | The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. <i>Cancer Cell</i> , <b>2013</b> , 23, 332-46   | 24.3 | 107 |
| 105 | Interaction domains of Sos1/Grb2 are finely tuned for cooperative control of embryonic stem cell fate. <i>Cell</i> , <b>2013</b> , 152, 1008-20  | 56.2 | 45  |
| 104 | Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. <i>Gynecologic Oncology</i> , <b>2013</b> , 129, 467-71                       | 4.9  | 35  |
| 103 | The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study. <i>Genetics in Medicine</i> , <b>2013</b> , 15, 458-65        | 8.1  | 21  |
| 102 | Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5960-71   | 12.9 | 79  |
| 101 | Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3474-84   | 12.9 | 67  |
| 100 | Siah2-deficient mice show impaired skin wound repair. <i>Wound Repair and Regeneration</i> , <b>2013</b> , 21, 437-47  | 3.6  | 5   |
| 99  | High levels of genomic aberrations in serous ovarian cancers are associated with better survival. <i>PLoS ONE</i> , <b>2013</b> , 8, e54356  | 3.7  | 14  |
| 98  | The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo. <i>PLoS ONE</i> , <b>2013</b> , 8, e66388                               | 3.7  | 24  |
| 97  | Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5806-15   | 12.9 | 118 |
| 96  | BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2654-63 | 2.2  | 810 |
| 95  | A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. <i>Cancer Research</i> , <b>2012</b> , 72, 66-75   | 10.1 | 158 |
| 94  | Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. <i>Cancer Research</i> , <b>2012</b> , 72, 3906-11  | 10.1 | 264 |

|    |   |      |      |
|----|---|------|------|
| 93 | LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. <i>Cancer Research</i> , <b>2012</b> , 72, 4060-73                                    | 10.1 | 73   |
| 92 | The changing view of high-grade serous ovarian cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 2701-4  | 10.1 | 122  |
| 91 | A role for common genomic variants in the assessment of familial breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4330-6  | 2.2  | 60   |
| 90 | Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5267-77   | 12.9 | 46   |
| 89 | Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy. <i>Cancer Research</i> , <b>2012</b> , 72, 1694-704   | 10.1 | 46   |
| 88 | Integrated genomic analyses of ovarian carcinoma. <i>Nature</i> , <b>2011</b> , 474, 609-15   | 50.4 | 5210 |
| 87 | Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia. <i>Molecular Cell</i> , <b>2011</b> , 44, 532-44  | 17.6 | 165  |
| 86 | Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. <i>PLoS ONE</i> , <b>2011</b> , 6, e18064   | 3.7  | 143  |
| 85 | Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 719-25  | 31.3 | 893  |
| 84 | The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. <i>Oncogene</i> , <b>2011</b> , 30, 2810-22   | 9.2  | 212  |
| 83 | IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2538-48                                      | 12.9 | 182  |
| 82 | Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2253-8 | 2.2  | 37   |
| 81 | Siah1/SIP regulates p27(kip1) stability and cell migration under metabolic stress. <i>Cell Cycle</i> , <b>2011</b> , 10, 2592-602   | 4.7  | 29   |
| 80 | Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. <i>PLoS ONE</i> , <b>2011</b> , 6, e17617                         | 3.7  | 28   |
| 79 | Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. <i>PLoS ONE</i> , <b>2011</b> , 6, e21121   | 3.7  | 63   |
| 78 | The genesis and evolution of high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , <b>2010</b> , 10, 803-8   | 31.3 | 297  |
| 77 | Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. <i>PLoS ONE</i> , <b>2010</b> , 5, e11408  | 3.7  | 73   |
| 76 | Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. <i>PLoS ONE</i> , <b>2010</b> , 5, e15498                        | 3.7  | 76   |



|    |   |      |      |
|----|---|------|------|
| 75 | ARID1A mutations in endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1532-43  | 59.2 | 1208 |
| 74 | Profiling the cancer genome. <i>Annual Review of Genomics and Human Genetics</i> , <b>2010</b> , 11, 133-59   | 9.7  | 36   |
| 73 | Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. <i>Cancer Cell</i> , <b>2010</b> , 18, 23-38  | 24.3 | 161  |
| 72 | SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. <i>Cancer Cell</i> , <b>2010</b> , 18, 109-21  | 24.3 | 101  |
| 71 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. <i>Journal of Pathology</i> , <b>2010</b> , 221, 49-56   | 9.4  | 485  |
| 70 | Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1417-27                       | 12.9 | 217  |
| 69 | Oncogenic pathway combinations predict clinical prognosis in gastric cancer. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000676   | 279  |      |
| 68 | Siah proteins: novel drug targets in the Ras and hypoxia pathways. <i>Cancer Research</i> , <b>2009</b> , 69, 8835-8  | 10.1 | 65   |
| 67 | Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. <i>Cancer Cell</i> , <b>2009</b> , 16, 115-25  | 24.3 | 366  |
| 66 | An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response. <i>Nature Cell Biology</i> , <b>2009</b> , 11, 85-91  | 23.4 | 113  |
| 65 | Inhibition of Siah ubiquitin ligase function. <i>Oncogene</i> , <b>2009</b> , 28, 289-96  | 9.2  | 65   |
| 64 | Mutation of FOXL2 in granulosa-cell tumors of the ovary. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2719-29  | 59.2 | 551  |
| 63 | Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5198-208   | 12.9 | 1044 |
| 62 | Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 1678-90                  | 6.6  | 93   |
| 61 | Siah proteins induce the epidermal growth factor-dependent degradation of phospholipase Cepsilon. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 1034-42   | 5.4  | 14   |
| 60 | The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 16713-8 | 11.5 | 81   |
| 59 | The challenges of gene expression microarrays for the study of human cancer. <i>Cancer Cell</i> , <b>2006</b> , 9, 333-9  | 24.3 | 80   |
| 58 | Elucidation of the substrate binding site of Siah ubiquitin ligase. <i>Structure</i> , <b>2006</b> , 14, 695-701  | 5.2  | 59   |



|    |  |      |     |
|----|--|------|-----|
| 57 | Differential expression of selected histone modifier genes in human solid cancers. <i>BMC Genomics</i> , <b>2006</b> , 7, 90   | 4.5  | 186 |
| 56 | Topological and functional discovery in a gene coexpression meta-network of gastric cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 232-41  | 10.1 | 68  |
| 55 | A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5129-35                                     | 12.9 | 39  |
| 54 | The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 829-34  | 8.7  | 43  |
| 53 | TGF-beta, c-Cbl, and PDGFR-alpha the in mammary stroma. <i>Developmental Biology</i> , <b>2005</b> , 279, 58-72  | 3.1  | 26  |
| 52 | Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 42, 247-59                                  | 5    | 85  |
| 51 | Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 3697-702 | 11.5 | 451 |
| 50 | The retinoid anticancer signal: mechanisms of target gene regulation. <i>British Journal of Cancer</i> , <b>2005</b> , 93, 310-8   | 8.7  | 38  |
| 49 | An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. <i>Cancer Research</i> , <b>2005</b> , 65, 4031-40   | 10.1 | 178 |
| 48 | Regulation of 2-oxoglutarate (alpha-ketoglutarate) dehydrogenase stability by the RING finger ubiquitin ligase Siah. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 53782-8   | 5.4  | 46  |
| 47 | Osteopenia in Siah1a mutant mice. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 29583-8  | 5.4  | 9   |
| 46 | Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. <i>Journal of Cell Biology</i> , <b>2004</b> , 167, 925-34   | 7.3  | 180 |
| 45 | Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. <i>Cell</i> , <b>2004</b> , 117, 941-52  | 56.2 | 333 |
| 44 | Expression and tyrosine phosphorylation of Cbl regulates macrophage chemokinetic and chemotactic movement. <i>Journal of Cellular Physiology</i> , <b>2003</b> , 195, 276-89   | 7    | 37  |
| 43 | A mouse with a loss-of-function mutation in the c-Cbl TKB domain shows perturbed thymocyte signaling without enhancing the activity of the ZAP-70 tyrosine kinase. <i>Journal of Experimental Medicine</i> , <b>2003</b> , 197, 503-13       | 16.6 | 45  |
| 42 | Generation and analysis of Siah2 mutant mice. <i>Molecular and Cellular Biology</i> , <b>2003</b> , 23, 9150-61  | 4.8  | 58  |
| 41 | A binding motif for Siah ubiquitin ligase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 3101-6  | 11.5 | 111 |
| 40 | Cbl-mediated ubiquitylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 28950-60                                   | 5.4  | 164 |

|    |  |      |     |
|----|--|------|-----|
| 39 | Siah ubiquitin ligase is structurally related to TRAF and modulates TNF-alpha signaling. <i>Nature Structural Biology</i> , <b>2002</b> , 9, 68-75   |      | 113 |
| 38 | Stress-induced decrease in TRAF2 stability is mediated by Siah2. <i>EMBO Journal</i> , <b>2002</b> , 21, 5756-65   | 13   | 92  |
| 37 | Genomewide gene expression analysis using cDNA microarrays. <i>Methods in Molecular Medicine</i> , <b>2002</b> , 68, 195-204   |      | 2   |
| 36 | The ubiquitin ligase component Siah1a is required for completion of meiosis I in male mice. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 2294-303   | 4.8  | 80  |
| 35 | Normal p53 function in primary cells deficient for Siah genes. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 8155-64   | 4.8  | 30  |
| 34 | Regulation of STAT protein synthesis by c-Cbl. <i>Oncogene</i> , <b>2001</b> , 20, 7326-33   | 9.2  | 18  |
| 33 | Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. <i>Journal of Cell Biology</i> , <b>2001</b> , 152, 181-95    | 7.3  | 342 |
| 32 | A Drosophila analogue of v-Cbl is a dominant-negative oncoprotein in vivo. <i>Oncogene</i> , <b>2000</b> , 19, 3299-308.2  |      | 27  |
| 31 | Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 2105-10 | 11.5 | 134 |
| 30 | The Cbl proto-oncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 851-67                                | 4.8  | 100 |
| 29 | Options available--from start to finish--for obtaining expression data by microarray. <i>Nature Genetics</i> , <b>1999</b> , 21, 25-32   | 36.3 | 383 |
| 28 | The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. <i>EMBO Journal</i> , <b>1999</b> , 18, 3616-28                                     | 13   | 238 |
| 27 | Activation of Ras and its downstream extracellular signal-regulated protein kinases by the CDC25 homology domain of mouse Son-of-sevenless 1 (mSos1). <i>Oncogene</i> , <b>1998</b> , 16, 2597-607                   | 9.2  | 14  |
| 26 | Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. <i>Molecular and Cellular Biology</i> , <b>1998</b> , 18, 4872-82  | 4.8  | 339 |
| 25 | Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. <i>Human Molecular Genetics</i> , <b>1997</b> , 6, 2011-9                         | 5.6  | 480 |
| 24 | Mutation in Sos1 dominantly enhances a weak allele of the EGFR, demonstrating a requirement for Sos1 in EGFR signaling and development. <i>Genes and Development</i> , <b>1997</b> , 11, 309-20                      | 12.6 | 58  |
| 23 | A c-Cbl yeast two hybrid screen reveals interactions with 14-3-3 isoforms and cytoskeletal components. <i>Biochemical and Biophysical Research Communications</i> , <b>1997</b> , 240, 46-50                         | 3.4  | 24  |
| 22 | Chromosomal mapping of five highly conserved murine homologues of the Drosophila RING finger gene seven-in-absentia. <i>Genomics</i> , <b>1997</b> , 41, 160-8   | 4.3  | 30  |

|    |   |      |     |
|----|---|------|-----|
| 21 | The solution structure of the pleckstrin homology domain of mouse Son-of-sevenless 1 (mSos1). <i>Journal of Molecular Biology</i> , <b>1997</b> , 269, 579-91   | 6.5  | 48  |
| 20 | A search for a mammalian homologue of the Drosophila photoreceptor development gene glass yields Zfp64, a zinc finger encoding gene which maps to the distal end of mouse chromosome 2. <i>Gene</i> , <b>1997</b> , 185, 11-7                               | 3.8  | 7   |
| 19 | D-Cbl, the Drosophila homologue of the c-Cbl proto-oncogene, interacts with the Drosophila EGF receptor in vivo, despite lacking C-terminal adaptor binding sites. <i>Oncogene</i> , <b>1997</b> , 14, 2709-19  | 9.2  | 58  |
| 18 | A dominant-negative mutant of mSOS1 inhibits insulin-induced Ras activation and reveals Ras-dependent and -independent insulin signaling pathways. <i>Molecular and Cellular Biology</i> , <b>1995</b> , 15, 379-88   | 4.8  | 58  |
| 17 | A combined genetic and biochemical approach to mammalian signal transduction. <i>Australian and New Zealand Journal of Medicine</i> , <b>1995</b> , 25, 845-51  |      | 1   |
| 16 | Mammalian homologues of the Drosophila Son of sevenless gene map to murine chromosomes 17 and 12 and to human chromosomes 2 and 14, respectively. <i>Genomics</i> , <b>1993</b> , 18, 14-9  | 4.3  | 21  |
| 15 | The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. <i>Nature</i> , <b>1993</b> , 363, 83-5   | 50.4 | 988 |
| 14 | Identification of murine homologues of the Drosophila son of sevenless gene: potential activators of ras. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1992</b> , 89, 6511-5                                 | 11.5 | 267 |
| 13 | Analysis of the enhancer element that controls expression of sevenless in the developing Drosophila eye. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 6853-7                                  | 11.5 | 30  |
| 12 | Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. <i>Cell</i> , <b>1991</b> , 67, 701-16  | 56.2 | 780 |
| 11 | Comparison of the sevenless genes of Drosophila virilis and Drosophila melanogaster. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1990</b> , 87, 5351-3  | 11.5 | 38  |
| 10 | Ommatidia in the developing Drosophila eye require and can respond to sevenless for only a restricted period. <i>Cell</i> , <b>1989</b> , 56, 931-6   | 56.2 | 64  |
| 9  | Regulation of the complex pattern of sevenless expression in the developing Drosophila eye. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1989</b> , 86, 6245-9   | 11.5 | 46  |
| 8  | Structure and activity of the sevenless protein: a protein tyrosine kinase receptor required for photoreceptor development in Drosophila. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1989</b> , 86, 8333-7 | 11.5 | 57  |
| 7  | Nucleotide sequence and structure of the sevenless gene of Drosophila melanogaster. <i>Genes and Development</i> , <b>1988</b> , 2, 620-34  | 12.6 | 82  |
| 6  | Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. <i>Journal of Virology</i> , <b>1988</b> , 62, 2464-73  | 6.6  | 92  |
| 5  | Localization of the sevenless protein, a putative receptor for positional information, in the eye imaginal disc of Drosophila. <i>Cell</i> , <b>1987</b> , 51, 143-50   | 56.2 | 247 |
| 4  | Rapid isolation of eukaryotic DNA. <i>Analytical Biochemistry</i> , <b>1987</b> , 162, 463-5  | 3.1  | 167 |

|   |  |     |    |
|---|--|-----|----|
| 3 | Immunization against <i>Taenia taeniaeformis</i> in mice: studies on the characterization of antigens from oncospheres. <i>International Journal for Parasitology</i> , <b>1984</b> , 14, 321-33 | 4.3 | 58 |
| 2 | <i>Taenia taeniaeformis</i> : immunoprecipitation analysis of the protein antigens of oncospheres and larvae. <i>Experimental Parasitology</i> , <b>1983</b> , 56, 416-27                        | 2.1 | 23 |
| 1 | Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors  |     | 2  |